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Abstract
 
Neurofibromatosis type 1 (NF1) is a common autosomal-dominant disorder characterized by
cutaneous neurofibromas infiltrated with large numbers of mast cells, melanocyte hyperplasia,
and a predisposition to develop malignant neoplasms. 
 
NF1
 
 encodes a GTPase activating pro-
tein (GAP) for Ras. Consistent with Knudson’s “two hit” model of tumor suppressor genes,
leukemias and malignant solid tumors in NF1 patients frequently demonstrate somatic loss of
the normal 
 
NF1
 
 allele. However, the phenotypic and biochemical consequences of heterozy-
gous inactivation of 
 
Nf1
 
 are largely unknown. Recently neurofibromin, the protein encoded
by 
 
NF1
 
, was shown to negatively regulate Ras activity in 
 
Nf1
 
2
 
/
 
2
 
 murine myeloid hemato-
poietic cells in vitro through the c-kit receptor tyrosine kinase (
 
dominant white spotting
 
,
 
 W
 
).
Since the 
 
W
 
 and 
 
Nf1
 
 locus appear to function along a common developmental pathway, we
generated mice with mutations at both loci to examine potential interactions in vivo. Here, we
show that haploinsufficiency at 
 
Nf1
 
 perturbs cell fates in mast cells in vivo, and partially rescues
coat color and mast cell defects in 
 
W
 
41
 
 mice. Haploinsufficiency at 
 
Nf1
 
 also increased mast cell
proliferation, survival, and colony formation in response to Steel factor, the ligand for c-kit.
Furthermore, haploinsufficiency was associated with enhanced Ras–mitogen-activated protein
kinase activity, a major downstream effector of Ras, via wild-type and mutant (
 
W
 
41
 
) c-kit re-
ceptors.
 
 
 
These observations identify a novel interaction between c-kit and neurofibromin in
vivo, and offer experimental evidence that haploinsufficiency of 
 
Nf1
 
 alters both cellular and
biochemical phenotypes in two cell lineages that are affected in individuals with NF1. Collec-
tively, these data support the emerging concept that heterozygous inactivation of tumor sup-
pressor genes may have profound biological effects in multiple cell types. 
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Introduction
 
Neurofibromin, the protein encoded by neurofibromatosis
type 1 (NF1), negatively regulates Ras output by accelerat-
ing the conversion of Ras-GTP to Ras-GDP (1, 2). The
murine c-kit receptor (3) and its ligand, Steel factor (4, 5),
are components of a signaling pathway that is essential for
murine hematopoiesis, melanogenesis, and gametogenesis.
These proteins are encoded by the 
 
dominant white spotting
 
(
 
W
 
) and 
 
Steel
 
 (
 
Sl
 
) loci, respectively, and ligand binding to
c-kit activates Ras in myeloid lineage cells (for a review,
see reference 6). Children with NF1 are at a markedly in-
creased risk of developing juvenile myelomonocytic leu-
kemia (JMML [7]). Genetic and biochemical analyses of
these leukemias strongly support the hypothesis that 
 
NF1
 
functions as a tumor suppressor gene in immature myeloid
cells by negatively regulating Ras output. Similarly, 
 
z
 
10%
of heterozygous 
 
Nf1
 
1
 
/
 
2
 
 mice spontaneously develop a
JMML-like myeloproliferative disorder (MPD) during the
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second year of life with loss of the wild-type 
 
Nf1
 
 allele (8).
In contrast to patients with NF1, 
 
Nf1
 
1
 
/
 
2
 
 mice neither
manifest pigmentary abnormalities nor develop neurofibromas
(8). Although homozygous 
 
Nf1
 
 knockout mice (
 
Nf1
 
2
 
/
 
2
 
)
die in utero around embryonic day (E)13.5 from complex car-
diovascular defects (8, 9), adoptive transfer of E13.5 
 
Nf1
 
2
 
/
 
2
 
fetal liver hematopoietic stem cells into irradiated syngeneic
recipients consistently induces the JMML-MPD (10). In-
terestingly, we have shown recently that murine 
 
Nf1
 
2
 
/
 
2
 
fetal liver cells form excessive numbers of myeloid progen-
itor colonies in methylcellulose cultures containing low
concentrations of Steel factor. Mitogen-activated protein
(MAP) kinase, a downstream target of Ras-GTP, is activated
in unstimulated 
 
Nf1
 
2
 
/
 
2
 
 myeloid lineage cells, and this ki-
nase is hyperactivated in response to several hematopoietic
growth factors, including GM-CSF and Steel factor (11).
This observation and the involvement of myeloid, mast
cell, and melanocyte lineages in some of the pathological
complications of NF1 led us to generate mice with muta-
tions at both 
 
W
 
 and 
 
Nf1
 
 to examine potential genetic and
biochemical interactions in vivo
 
 
 
and in vitro.
 
Materials and Methods
 
Animals.
 
 
 
Nf1
 
1
 
/
 
2
 
 mice were obtained from Dr. Tyler Jacks
at the Massachusetts Institute of Technology (Cambridge, MA) in
a C57BL/6.129 background, and were backcrossed for 13 gener-
ations into the C57BL/6 strain. C57BL/6
 
1
 
/
 
1
 
;
 
W
 
41
 
/W
 
41
 
 mice
were obtained from the Jackson Laboratory. These studies were
conducted with a protocol approved by the Indiana University
Laboratory Animal Research Center. The 
 
Nf1 
 
allele was geno-
typed as described previously (11, 12). The 
 
W
 
41
 
 genotyping was
inferred from the characteristic mottled, white coat color in 
 
W
 
41
 
/
W
 
41 
 
mice, and a white abdominal spot on 
 
W
 
41
 
/
 
1
 
 mice. Multiple
F0 founders were used to generate the F2 progeny used in these
experiments. The crosses used to generate the four 
 
Nf1
 
 and 
 
W
 
genotypes used in these experiments are outlined below: 
F0:
 
Nf1
 
1
 
/
 
2
 
;
 
1
 
/
 
1
 
 
 
3
 
 
 
1
 
/
 
1
 
;
 
W
 
41
 
/W
 
41
 
F1:
 
Nf1
 
1
 
/
 
2
 
;
 
W
 
41
 
/
 
1
 
 
 
3
 
 
 
1
 
/
 
1
 
;
 
W
 
41
 
/
 
1
 
F2:
 
Nf1
 
1
 
/
 
2
 
;
 
W
 
41
 
/W
 
41, 1/1;W41/W41,
Nf11/2;1/1, 1/1;1/1.
Analysis of Cutaneous Mast Cells.  1-cm sections of ears and
dorsal skin were removed, fixed in buffered formalin, and pro-
cessed in paraffin-embedded sections. Specimens were stained with
hematoxylin-eosin to assess routine histology, and with Giemsa
to identify mast cells. Some specimens were stained with Fontana-
Masson to differentiate melanin-containing cells from mast cells.
Cutaneous mast cells (Giemsa-positive, Fontana-Masson–nega-
tive) were quantitated in a blinded fashion by counting the distal
5 mm of ears or dorsal skin.
Peritoneal Lavages and Mast Cell Colony Assays.  Peritoneal cells
from 8-wk-old mice were collected as described previously (13).
10-ml peritoneal lavages were then concentrated by centrifuga-
tion and stained with toluidine blue to quantify total number of
mast cells per 10 ml lavage. To examine the proliferation of peri-
toneal cells for mast cell progenitors, mast cell colony assays were
done in triplicate. In brief, 1 ml of culture mix containing 1 3
104 peritoneal cells, a-MEM, 1.2% methylcellulose (Terry Fox
Laboratory), 30% fetal bovine serum (HyClone Laboratories), 1%
deionized fraction V BSA (Sigma Chemical Co.), 1024 M mercap-
toethanol (Sigma Chemical Co.), 10 ng/ml of recombinant
murine IL-3, and 100 ng/ml of recombinant murine Steel factor
(PeproTech) was plated in each 35-mm suspension culture dish
(Nalge Nunc International), then incubated at 378C in a humidi-
fied atmosphere flush with 5% CO2 in air. Colonies were deter-
mined on day 14 of incubation by in situ observation using an in-
verted microscope. To assess the accuracy of in situ identification
of the colonies, individual colonies were taken with an Eppen-
dorf micropipette under direct microscope visualization, spread
on glass slides using cytocentrifuge, and stained with May-Grun-
wald-Giemsa stain and Alcian blue/safranin stain for mast cells.
Bone Marrow Mast Cell Culture and Survival Assay.  Six lines from
each of the four genotypes were generated and used for cell sur-
vival and proliferation assays. Bone marrow mast cells (BMMCs)
were cultured as described, with minor modifications (14), and
homogeneity of BMMCs was determined by Giemsa staining.
Aliquots of cells were also stained with Alcian blue and safranin to
confirm that they were mast cells. Furthermore, FACS® analysis
revealed similar forward and side light scatter characteristics and
the same percentage of c-kit1 cells in BMMCs of all four geno-
types (data not shown). The mast cell survival assay was done as
follows: BMMCs from each genotype were deprived of growth
factors for 24 h, and 3 3 105 cells were plated in 24-well dishes in
serum-free RPMI containing 1% glutamine and 100 ng/ml of re-
combinant murine Steel factor in a total volume of 1 ml. The
number of surviving cells was determined by trypan blue exclu-
sion at 48 h of culture in a 378C, 5% CO2, humidified incubator.
Proliferation Assay.  Proliferation assays were performed as de-
scribed previously (14). BMMCs were deprived of growth factors
for 24 h, and 2 3 105 cells were plated in triplicate in 24-well
dishes in 1 ml RPMI containing 1% glutamine, 10% fetal bovine
serum, and 100 ng/ml recombinant murine Steel factor or no
growth factors as indicated in a 378C, 5% CO2, humidified incuba-
tor. After 1 and 3 d, viable cells were counted using a hemocytom-
eter. Cell viability was determined by a trypan blue exclusion assay.
Analysis of p42 MAP Kinase Activation.  Activation of p42 MAP
kinase was determined by depriving cells of growth factors for 24 h
and stimulating them with 10 ng/ml of recombinant murine Steel
factor for various amounts of time. Cells were collected and
washed twice with cold PBS plus 1 mM sodium orthovandate,
and then lysed in nonionic lysis buffer as described previously
(15). The protein lysates were equalized for total protein concen-
tration using a BCA assay (Pierce Chemical Co.), and equal load-
ing of MAP kinases in these assays was confirmed by Western blot.
p42 MAP kinase immunoprecipitations were carried out with an
anti–extracellular signal–regulatory kinase (ERK)-2 (C-14) anti-
body (Santa Cruz Biotechnology). The p42 MAP kinase immune
complex assay was performed as described, except that Elk-1 fu-
sion protein (New England Biolabs) was used instead of myelin
basic protein. The kinase reactions were resolved on 10% SDS-
PAGE gels. Gels were dried and subjected to autoradiography.
Densitometry of individual bands was conducted using NIH Im-
age software.
Results
Haploinsufficiency at Nf1 Partially Restores the Coat Color Defi-
ciency in W41 Mice. W mice display varying degrees of steril-
ity, mast cell hypoplasia, anemia, and coat color deficiency
correlating with the residual kinase activity of the mutant re-
ceptor (16, 17). Mice homozygous for a point mutation in the183 Ingram et al. Brief Definitive Report
cytoplasmic domain of the c-kit receptor (W41) have partial
inactivation of the c-kit receptor tyrosine kinase, resulting in
an abnormal mottled, white coat color (17). We crossed W41
and Nf1 mice and found that animals heterozygous at Nf1 and
homozygous for the W41  mutation (Nf11/2;W41/W41)
displayed a 60–70% restoration of coat color (Fig. 1 A).
This finding was consistent in .150 F2 progeny carrying mu-
tations at both loci. Thus, haploinsufficiency at Nf1 partially
corrects the aberrant pigmentation pattern of W41/W41 mice.
Haploinsufficiency at Nf1 Increases Peritoneal and Cutaneous
Mass Cell Numbers in Wild-Type and W41 Mice.  Mice ho-
mozygous for different mutant W alleles have reduced
numbers of peritoneal and cutaneous mast cells (17, 18).
To investigate whether heterozygous inactivation of Nf1
could modulate the deficiency of this lineage, we compared
numbers of peritoneal mast cells harvested from Nf11/2;
W41/W41 animals to those taken from singly mutant mice
(1/1;W41/W41). We also compared peritoneal mast cell
numbers in Nf11/2;1/1 and wild-type mice. Cells iso-
lated by peritoneal lavage were stained with toluidine blue
to identify mast cells. Representative cytospins from indi-
vidual mice from each of the four Nf1 and W genotypes
are shown in Fig. 1 B. Peritoneal mast cell numbers in
Nf11/2;W41/W41 mice were 40-fold higher than in 1/1;
W41/W41 littermates (Table I). Importantly, in addition to
restoring peritoneal mast cell numbers to z10% of wild-
type levels in W41/W41 mice, heterozygous inactivation of
Nf1 significantly increased mast cell numbers in animals that
were wild-type at the W locus (Table I). We performed sim-
ilar experiments to determine if haploinsufficiency at Nf1 in-
creased numbers of cutaneous mast cells in the mutant
W41/W41 and wild-type backgrounds. Giemsa-stained ear
biopsies from mice of the four W and Nf1 genotypes are
shown in Fig. 1 C. Ear biopsies from Nf11/2;W41/W41
mice showed a twofold increase in numbers of cutaneous
mast cells compared with 1/1;W41/W41 mice (Table I).
Nf11/2;1/1 mice also had a modest, though statistically
insignificant, increase in cutaneous mast cell numbers com-
pared with wild-type mice (Table I). Giemsa-stained biop-
sies obtained from a second site (dorsal skin) revealed simi-
lar differences in cutaneous mast cell numbers between the
genotypes (data not shown). The increased numbers of
peritoneal and cutaneous mast cells in Nf11/2 mice pro-
vide additional evidence that haploinsufficiency augments
signaling through the c-kit receptor in vivo.
Haploinsufficiency at Nf1 Increases Colony Formation, Prolif-
eration, and Survival of Mast Cells in Response to Steel Factor in
W41 and Wild-Type Mice.  IL-3 and Steel factor support
Figure 1. Effect of haploinsufficiency of Nf1 on coat color and total numbers of cutaneous and peritoneal mast cells. (A) Coat color pattern of a repre-
sentative mouse from each of the following genotypes: 1/1;1/1, Nf11/2;1/1, 1/1;W41/W41, and Nf11/2;W41/W41. Haploinsufficiency at Nf1
partially corrects the coat color deficiency in mice homozygous for the W41 allele in a C57BL/6 genetic background. (B) Representative cytospins from
peritoneal lavages stained for mast cells from individual mice of the four Nf1 and W genotypes. Peritoneal cells were stained with toluidine blue to quan-
tify the total number of mast cells per peritoneal lavage. A higher magnification of a representative mast cell is shown in the inset of the wild-type mouse
(original magnification: 3200). Bar (inset) 10 µm. Bar (far right) 30 µm. (C) Representative ear biopsies stained for cutaneous mast cells from individual
mice of the four Nf1 and W genotypes. Specimens were stained with hematoxylin-eosin to assess routine histology, and with Giemsa to identify mast
cells. Ear biopsies were stained with Fontana-Masson to differentiate melanin-containing cells from mast cells. Cutaneous mast cells (Giemsa-positive,
Fontana-Masson–negative) were quantitated in a blinded fashion by counting the distal 5 mm of ears. Black arrows indicate Giemsa-positive mast cells,
and open arrows indicate Fontana-Masson melanin–containing cells. Bar, 35 µm.184 Heterozygosity of Nf1 Modulates Melanocyte and Mast Cell Fates
clonal mast cell colony formation from bone marrow and
mature mast cells in vitro. To further characterize interac-
tions between W and Nf1, we assessed the ability of perito-
neal cells isolated from mice of all four genotypes to form
mast cell colonies in methylcellulose cultures (13). No mast
cell progenitor colonies formed in cultures of 1/1;W41/W41
peritoneal cells (Table I). In contrast, cells from Nf11/2;
W41/W41 mice formed significant numbers of mast cell col-
onies in this assay. Heterozygous inactivation of Nf1 also
significantly enhanced the growth of mast cell colonies in
mice that were wild-type at the W locus (Table I).
C-kit receptor activation in BMMCs mediates diverse
biological responses, including proliferation. To assess whether
haploinsufficiency at Nf1 augments the proliferative re-
sponses of a homogeneous population of mast cells to Steel
factor, the growth kinetics of Nf11/2 BMMCs were com-
pared with Nf11/1 cells in mice with a normal or mutant
(W41) c-kit receptor. BMMCs from mice of each genotype
were cultured in 10% FCS without added growth factors
for 24 h before the addition of Steel factor. Cell numbers
were determined at the time Steel factor was added (day 0)
and after 24 and 72 h in culture. Nf11/2 cells of both W
genotypes showed greater proliferative responses to Steel
factor after 24 and 72 h in culture than the corresponding
Nf11/1 populations (Fig. 2 A). Using the same experimen-
tal design, thymidine incorporation assays gave similar re-
sults (data not shown). Thus, haploinsufficiency at Nf1 is
associated with an increased proliferative response of wild-
Table I. Effects of W and Nf1 Genotypes on Mast Cell Numbers and Mast Cell Colony Growth
Genotype
1/1
1/1
Nf11/2
1/1
1/1
W41/W41
Nf11/2
W41/W41
No. of peritoneal mast cells (3102) 780 6 10 1,000 6 14* 2 6 1 81 6 17*
No. of cutaneous mast cells (mm2) 25.6 6 7 31 6 26  6 1 14 6 2*
No. of mast cell colonies (3102) 79 6 6 117 6 9* 08   6 0.8*
Nos. of peritoneal and cutaneous mast cells were quantitated from peritoneal lavages and ear biopsies. Results represent mean numbers of mast cells 6
SEM from six animals in each genotype. Peritoneal cells were cultured for the growth of mast cell colonies as described (reference 13), and results
represent the mean number of mast cell colonies 6 SEM of six independent experiments.
*P , 0.05 for comparison of Nf11/1 and Nf11/2 in both W41/W41 and wild-type genetic backgrounds by Student’s paired t test.
Figure 2. Effect of haploinsufficiency of Nf1 and W on the survival and proliferation of BMMCs in response to Steel factor. (A) Proliferation of BMMCs
from mice of the four Nf1 and W genotypes in response to recombinant murine Steel factor. After deprivation of growth factors for 24 h, 2 3 105 cells/ml
were plated in triplicate in 24-well dishes in RPMI containing 1% glutamine, 10% fetal bovine serum, and 100 ng/ml of Steel factor in a total volume of
1 ml as described previously (reference 29). After 1 and 3 d, viable cells were counted using a hemocytometer and expressed as a percentage of input cells.
*P , 0.05, Nf11/2;W41/W41 vs. 1/1;W41/W41 and Nf11/2;1/1 vs. 1/1;1/1 cells by Student’s paired t test. (B) Percent survival of BMMCs of
the four Nf1 and W genotypes. After deprivation of growth factors for 24 h, 3 3 105 cells of each genotype were plated in RPMI containing 1% BSA and
100 ng/ml of recombinant murine Steel factor. The number of surviving cells was determined by trypan blue exclusion and expressed as a percentage of
input cells. *P , 0.05, Nf11/2;W41/W41 vs. 1/1;W41/W41 and Nf11/2;1/1 vs. 1/1;1/1 cells by Student’s paired t test.185 Ingram et al. Brief Definitive Report
type and W41/W41 BMMCs in liquid cultures containing
10% FCS and exogenous Steel factor.
Steel factor acts as both a mitogen and a survival factor
for mast cells (5, 17, 19). Mast cells derived from different
lines of W mutant mice display reduced or no survival when
cultured in the presence of Steel factor alone, which corre-
lates with residual receptor tyrosine kinase activity (17, 19).
Therefore, we examined the effect of heterozygous inacti-
vation of Nf1 on the survival of BMMCs isolated from
wild-type and W41/W41 mice (Fig. 2 B). Nf11/2 BMMCs
of both W genotypes demonstrated increased survival
compared with Nf11/1 cells after 48 h of culture in se-
rum-free media in response to exogenous Steel factor.
Since this assay has been shown to correlate with c-kit re-
ceptor tyrosine kinase activity (19), we quantitated surface
expression of c-kit on the four W and Nf1 genotypes by
fluorescence cytometry to ensure that these differences in
cell survival were not explained by variable levels of receptor
expression. No differences were observed (data not shown).
Haploinsufficiency at Nf1 Increases MAP Kinase Activity in
Response to Steel Factor in Wild-Type and W41 Mice.  The data
presented above provide evidence that haploinsufficiency
of Nf1 augments the proliferation and survival of wild-type
and W41/W41 mast cells in vitro and in vivo. Partial restora-
tion of normal coat color in Nf11/2;W41/W41 mice indi-
cates that this effect is not restricted to hematopoietic cells,
but also includes melanocytes. The Ras-MAP kinase path-
way is an important downstream target of c-kit receptor
activation, and neurofibromin negatively regulates Ras sig-
naling by functioning as a GTPase activating protein (GAP)
for Ras (20, 21). The phenotypic data presented above sug-
gest a model whereby heterozygous inactivation of Nf1 en-
hances c-kit–induced Ras output by reducing neurofibro-
min levels (and GAP activity for Ras) in susceptible cell
lineages. To test this hypothesis, we stimulated primary
BMMCs with Steel factor, and measured p42 MAP kinase.
MAP kinase protein levels were similar in BMMCs of all
genotype combinations (data not shown). Nf11/2;W41/W41
BMMCs demonstrated a fivefold greater increase in MAP
kinase activity from baseline 5 min after the addition of
Steel factor relative to 1/1;W41/W41 BMMCs (Fig. 3).
Indeed, haploinsufficiency of Nf1 restored the ability of the
mutant W41 c-kit receptor to activate MAP kinase to wild-
type levels at the 5-min time point (Fig. 3). Similarly,
Nf11/2;1/1 BMMCs had a twofold greater increase in
MAP kinase activity from baseline compared with wild-
type mast cells that was sustained at both tested time points
(Fig. 3). These biochemical data indicate that the phenotypic
effects in Nf11/2 mast cells correlate with enhanced sig-
naling through a major downstream effector of Ras-GTP.
Discussion
In these experiments, we present genetic, cellular, and
biochemical data demonstrating that neurofibromin nega-
tively regulates signaling through the c-kit receptor tyro-
sine kinase in a haploinsufficient state. Dermal cafe au lait
macules, learning disabilities, and the development of mul-
tiple cutaneous neurofibromas are major nonmalignant patho-
logic complications of NF1. Although the finding of con-
stitutional heterozygosity (LOH) in some neurofibromas
supports the “two hit” tumor suppressor model (22, 23),
many of these lesions retain the normal NF1 allele. Other
features of neurofibroma biology, including the very large
numbers of lesions found in some patients, their self-limited
growth, and the low propensity of these tumors to undergo
malignant degeneration are also consistent with a possible
dosage effect on cell growth. Neurofibromas are infiltrated
with mast cells that have been hypothesized to promote
growth by releasing mediators that act locally upon Schwann
cells, endothelial cells, and fibroblasts (24). Treatment with
mast cell stabilizers is associated with a reduction in pruritus
in some patients with NF1, and represents the only known
medical treatment that alters the growth of neurofibromas
(24). Given the importance of Steel factor in regulating
multiple mast cell functions, our data showing that haplo-
insufficiency at Nf1 alters mast cell numbers, survival, and
Ras signaling in wild-type and W41/W41 mice in response
to Steel factor implicate deregulated mast cell function as
potentially important in neurofibroma formation.
In a recent study, Hemesath et al. (25) implicated the
Micropthalmia (Mi) transcription factor as a direct target of
MAP kinase activation in response to c-kit. The observation
that haploinsufficiency at Nf1 effects a 60–70% rescue of
the pigmentary defect seen in W41/W41 mice further sup-
ports the central role of this pathway in melanocyte devel-
opment, and is consistent with the marked enhancement of
Figure 3. Analysis of p42 MAP kinase activity from BMMCs stimu-
lated with Steel factor in the four Nf1 and W genotypes. Activation of
p42 MAP kinase was determined by depriving cells of growth factors for
24 h, followed by stimulation with 10 ng/ml of Steel factor for 5 and 15
min. Autoradiography and quantitative densitometry of the phosphoryla-
tion of Elk-1 fusion protein by MAP kinase from lysates obtained from
Steel factor–stimulated BMMCs are shown. Data represent one of three
independent experiments. Similar results were obtained in two other ex-
periments.186 Heterozygosity of Nf1 Modulates Melanocyte and Mast Cell Fates
Steel factor–induced MAP kinase activation that we ob-
served in Nf11/2 mast cells. Although the molecular basis
of cutaneous melanocyte hyperplasia in NF1 is poorly un-
derstood, our data suggest that melanocytes from Nf11/2
mice could offer an attractive system for discerning the role
of Nf1 in examining the c-kit–MAP kinase–Mi pathway.
The relative contributions of homozygous NF1 inactiva-
tion and of haploinsufficiency to the pathologic complica-
tions of NF1 remain incompletely understood. Genetic
analysis of malignant peripheral nerve sheath tumors (MP-
NSTs), pheochromocytomas, and myeloid leukemias from
individuals with NF1 and Nf11/2 mice have demonstrated
frequent somatic loss of the normal allele (8, 26–29). Ho-
mozygous inactivation of NF1 in a human MPNST, in
several leukemias, and in a variety of murine tumors pro-
vides formal proof that the gene functions as a tumor sup-
pressor in a subset of cancers (8, 30). Although these data
confirm that tumorigenesis follows the Knudson paradigm
(31) in some patients and in Nf1 mice, many tumors do not
show loss of LOH, and it is uncertain if inactivation of both
alleles is a prerequisite for tumor formation. In a recent
study of heterozygous p53 knockout mice, some tumors
retained a functional p53 allele (32). Tumor formation in
p27 knockout mice is also associated with haploinsuffiency
(33). The phenotypes that we have detected in Nf11/2 cells
of two lineages suggest that haploinsufficiency may confer a
growth advantage that could contribute to tumorigenesis
by pathways that do not require inactivation of the normal
allele. Full genetic and biochemical characterization of tu-
mors from patients with NF1 and from Nf11/2 mice that
retain heterozygosity is required to address this possibility.
Finally, the finding that haploinsufficiency at Nf1 has dra-
matic phenotypic consequences in two cell lineages that are
affected in NF1 patients has important therapeutic implica-
tions. In particular, if diseased cells retain a functional NF1
allele, increasing neurofibromin-specific GAP activity is an
attractive strategy for preventing or treating the complica-
tions of NF1.
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